{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T05:21:19Z","timestamp":1791523279471,"version":"4.3.4"},"reference-count":60,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2024-02766"],"award-info":[{"award-number":["2024-02766"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006733","name":"Indiana University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006733","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001455","name":"American Foundation for Suicide Prevention","doi-asserted-by":"publisher","award":["DIG-1-037-19"],"award-info":[{"award-number":["DIG-1-037-19"]}],"id":[{"id":"10.13039\/100001455","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biological Psychiatry Global Open Science"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.bpsgos.2026.100698","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T16:04:09Z","timestamp":1770480249000},"page":"100698","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacotherapies for Attention-Deficit\/Hyperactivity Disorder and Risk of Suicidal Behavior: A Within-Individual Study of Stimulants, Atomoxetine, and Alpha-2 Agonists"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3914-8235","authenticated-orcid":false,"given":"Sydney M.","family":"Adams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Meraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren M.","family":"O\u2019Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tennisha","family":"Riley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Froehlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick D.","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian M.","family":"D\u2019Onofrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bpsgos.2026.100698_bib1","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1080\/15374416.2024.2335625","article-title":"ADHD prevalence among U.S. Children and adolescents in 2022: Diagnosis, severity, co-occurring disorders, and treatment","volume":"53","author":"Danielson","year":"2024","journal-title":"J Clin Child Adolesc Psychol"},{"key":"10.1016\/j.bpsgos.2026.100698_bib2","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1176\/appi.ajp.2021.21010032","article-title":"Variable patterns of remission from ADHD in the multimodal treatment study of ADHD","volume":"179","author":"Sibley","year":"2022","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.bpsgos.2026.100698_bib3","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.neubiorev.2019.05.022","article-title":"Association between suicidal spectrum behaviors and attention-deficit\/hyperactivity disorder: A systematic review and meta-analysis","volume":"103","author":"Septier","year":"2019","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.bpsgos.2026.100698_bib4","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1001\/jamapsychiatry.2023.5045","article-title":"Trends in incident prescriptions for behavioral health medications in the US, 2018-2022","volume":"81","author":"Chai","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.bpsgos.2026.100698_bib5","doi-asserted-by":"crossref","first-page":"327","DOI":"10.15585\/mmwr.mm7213a1","article-title":"Trends in stimulant prescription fills among commercially insured children and adults - United States, 2016-2021","volume":"72","author":"Danielson","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.bpsgos.2026.100698_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101780","article-title":"Attention-deficit\/hyperactivity disorder medication consumption in 64 countries and regions from 2015 to 2019: A longitudinal study","volume":"58","author":"Chan","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.bpsgos.2026.100698_bib7","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S2215-0366(18)30269-4","article-title":"Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: A systematic review and network meta-analysis","volume":"5","author":"Cortese","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.bpsgos.2026.100698_bib8","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.neubiorev.2021.01.022","article-title":"The World Federation of ADHD international consensus statement: 208 Evidence-based conclusions about the disorder","volume":"128","author":"Faraone","year":"2021","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.bpsgos.2026.100698_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0180355","article-title":"The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review with network meta-analyses of randomised trials","volume":"12","author":"Catal\u00e1-L\u00f3pez","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.bpsgos.2026.100698_bib10","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1007\/s00787-017-0986-y","article-title":"Systematic review of quality of life and functional outcomes in randomized placebo-controlled studies of medications for attention-deficit\/hyperactivity disorder","volume":"26","author":"Coghill","year":"2017","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"10.1016\/j.bpsgos.2026.100698_bib11","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.biopsych.2019.04.009","article-title":"Risks and benefits of attention-deficit\/hyperactivity disorder medication on behavioral and neuropsychiatric outcomes: A qualitative review of pharmacoepidemiology studies using linked prescription databases","volume":"86","author":"Chang","year":"2019","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.bpsgos.2026.100698_bib12","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/jcpp.14056","article-title":"Research Review: Pharmacological and non-pharmacological treatments for adolescents with attention deficit\/hyperactivity disorder - A systematic review of the literature","volume":"66","author":"Sibley","year":"2025","journal-title":"J Child Psychol Psychiatry"},{"key":"10.1016\/j.bpsgos.2026.100698_bib13","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S2215-0366(24)00360-2","article-title":"Comparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: A systematic review and component network meta-analysis","volume":"12","author":"Ostinelli","year":"2025","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.bpsgos.2026.100698_bib14","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1007\/s40263-021-00848-3","article-title":"A practical, evidence-informed approach to managing stimulant-refractory attention deficit hyperactivity disorder (ADHD)","volume":"35","author":"Cortese","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1016\/j.bpsgos.2026.100698_bib15","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1017\/S1092852919001822","article-title":"Individualization of attention-deficit\/hyperactivity disorder treatment: Pharmacotherapy considerations by age and co-occurring conditions","volume":"26","author":"Mattingly","year":"2021","journal-title":"CNS Spectr"},{"key":"10.1016\/j.bpsgos.2026.100698_bib16","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jsat.2016.12.003","article-title":"Physician practices to prevent ADHD stimulant diversion and misuse","volume":"74","author":"Colaneri","year":"2017","journal-title":"J Subst Abuse Treat"},{"key":"10.1016\/j.bpsgos.2026.100698_bib17","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1089\/cap.2022.0009","article-title":"Association of coexisting conditions, attention-deficit\/hyperactivity disorder medication choice, and likelihood of improvement in preschool-age children: A developmental behavioral pediatrics research network study","volume":"32","author":"Deavenport-Saman","year":"2022","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.bpsgos.2026.100698_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g3769","article-title":"Drug treatment for attention-deficit\/hyperactivity disorder and suicidal behaviour: Register based study","volume":"348","author":"Chen","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.bpsgos.2026.100698_bib19","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.2859","article-title":"Attention-deficit\/hyperactivity disorder medications and work disability and mental health outcomes","volume":"7","author":"Taipale","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.bpsgos.2026.100698_bib20","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.biopsych.2019.12.003","article-title":"Medication for attention-deficit\/hyperactivity disorder and risk for suicide attempts","volume":"88","author":"Chang","year":"2020","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.bpsgos.2026.100698_bib21","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/chi.0b013e31815d88b2","article-title":"Meta-analysis of suicide-related behavior events in patients treated with atomoxetine","volume":"47","author":"Bangs","year":"2008","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.bpsgos.2026.100698_bib22","first-page":"124","article-title":"The statistics of suicide","volume":"25","author":"Gibbons","year":"2013","journal-title":"Shanghai Arch Psychiatry"},{"key":"10.1016\/j.bpsgos.2026.100698_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2021.113861","article-title":"Retrospective analysis of adverse events associated with non-stimulant ADHD medications reported to the United States Food and Drug Administration","volume":"300","author":"Pang","year":"2021","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.bpsgos.2026.100698_bib24","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3390\/neurolint15020043","article-title":"The role of Alpha-2 agonists for attention deficit hyperactivity disorder in children: A review","volume":"15","author":"Neuchat","year":"2023","journal-title":"Neurol Int"},{"key":"10.1016\/j.bpsgos.2026.100698_bib25","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2019-2832","article-title":"Attention-deficit\/hyperactivity disorder and psychotropic polypharmacy prescribing trends","volume":"146","author":"Girand","year":"2020","journal-title":"Pediatrics"},{"key":"10.1016\/j.bpsgos.2026.100698_bib26","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S2215-0366(24)00396-1","article-title":"Evaluating ADHD medication trial representativeness: A Swedish population-based study comparing hypothetically trial-eligible and trial-ineligible individuals","volume":"12","author":"Garcia-Argibay","year":"2025","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.bpsgos.2026.100698_bib27","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.4088\/JCP.09m05344pur","article-title":"Representativeness of participants in a clinical trial for attention-deficit\/hyperactivity disorder? Comparison with adults from a large observational study","volume":"71","author":"Surman","year":"2010","journal-title":"J Clin Psychiatry"},{"issue":"suppl 2S","key":"10.1016\/j.bpsgos.2026.100698_bib28","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1097\/DBP.0000000000000771","article-title":"Challenges and opportunities: Advancing the evidence base for the care of complex attention-deficit\/hyperactivity disorder","volume":"41","author":"Diekroger","year":"2020","journal-title":"J Dev Behav Pediatr"},{"key":"10.1016\/j.bpsgos.2026.100698_bib29","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S2215-0366(19)30096-3","article-title":"Emerging challenges in pharmacotherapy research on attention-deficit hyperactivity disorder-outcome measures beyond symptom control and clinical trials","volume":"6","author":"Wong","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.bpsgos.2026.100698_bib30","first-page":"714","article-title":"Methods to control for unmeasured confounding in pharmacoepidemiology: An overview","volume":"38","author":"Uddin","year":"2016","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.bpsgos.2026.100698_bib31","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1002\/pds.5110","article-title":"Attention-deficit\/hyperactivity disorder medication and risk of suicide attempt: A meta-analysis of observational studies","volume":"29","author":"Liu","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.bpsgos.2026.100698_bib32","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/jamapsychiatry.2017.2183","article-title":"Association of risk of suicide attempts with methylphenidate treatment","volume":"74","author":"Man","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.bpsgos.2026.100698_bib34","author":"Caucus"},{"key":"10.1016\/j.bpsgos.2026.100698_bib35","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2022-058375","article-title":"Youth suicide during the first year of the COVID-19 pandemic","volume":"151","author":"Bridge","year":"2023","journal-title":"Pediatrics"},{"key":"10.1016\/j.bpsgos.2026.100698_bib36","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1176\/appi.ps.20230113","article-title":"Racial-ethnic differences in ADHD diagnosis and treatment during adolescence and early adulthood","volume":"75","author":"Adams","year":"2024","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.bpsgos.2026.100698_bib37","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1097\/JCP.0000000000000759","article-title":"Determinants of pharmacological treatment initiation and persistence in publicly insured adults with attention-deficit\/hyperactivity disorder","volume":"37","author":"Li","year":"2017","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.bpsgos.2026.100698_bib38","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1001\/jamapsychiatry.2021.3815","article-title":"Neurodevelopmental disorders among publicly or privately insured children in the United States","volume":"79","author":"Straub","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.bpsgos.2026.100698_bib39","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1176\/appi.ps.201600469","article-title":"Racial-ethnic differences in patterns of discontinuous medication treatment among Medicaid-insured youths with ADHD","volume":"69","author":"Ji","year":"2018","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.bpsgos.2026.100698_bib40","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.0321","article-title":"Racial disparities in diagnosis of attention-deficit\/hyperactivity disorder in a US national birth cohort","volume":"4","author":"Shi","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.bpsgos.2026.100698_bib42","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1136\/amiajnl-2011-000116","article-title":"Normalized names for clinical drugs: RxNorm at 6 years","volume":"18","author":"Nelson","year":"2011","journal-title":"J Am Med Inform Assoc"},{"key":"10.1016\/j.bpsgos.2026.100698_bib43","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1177\/0009922813502123","article-title":"A review of the use of clonidine as a sleep aid in the child and adolescent population","volume":"53","author":"Nguyen","year":"2014","journal-title":"Clin Pediatr"},{"key":"10.1016\/j.bpsgos.2026.100698_bib44","doi-asserted-by":"crossref","DOI":"10.52965\/001c.38360","article-title":"Viloxazine for the treatment of attention deficit hyperactivity disorder","volume":"10","author":"Robinson","year":"2022","journal-title":"Health Psychol Res"},{"issue":"108","key":"10.1016\/j.bpsgos.2026.100698_bib45","first-page":"1","article-title":"Issues in developing a surveillance case definition for nonfatal suicide attempt and intentional self-harm using International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) coded data","author":"Hedegaard","year":"2018","journal-title":"Natl Health Stat Rep"},{"key":"10.1016\/j.bpsgos.2026.100698_bib46","unstructured":"Allison PD (2006): Fixed effects regression methods in SAS. Available at: https:\/\/support.sas.com\/resources\/papers\/proceedings\/proceedings\/sugi31\/184-31.pdf. Accessed December 16, 2025."},{"key":"10.1016\/j.bpsgos.2026.100698_bib47","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/sim.7536","article-title":"Investigating the assumptions of the self-controlled case series method","volume":"37","author":"Whitaker","year":"2018","journal-title":"Stat Med"},{"key":"10.1016\/j.bpsgos.2026.100698_bib48","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1146\/annurev-statistics-030718-105108","article-title":"Self-controlled case series methodology","volume":"6","author":"Whitaker","year":"2019","journal-title":"Annu Rev Stat Its Appl"},{"key":"10.1016\/j.bpsgos.2026.100698_bib49","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1080\/03007995.2021.1968814","article-title":"Treatment patterns among adults with attention-deficit\/hyperactivity disorder in the United States: A retrospective claims study","volume":"37","author":"Schein","year":"2021","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.bpsgos.2026.100698_bib50","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1001\/jamapsychiatry.2020.3995","article-title":"Association between race\/ethnicity and disparities in health care use before first-episode psychosis among privately insured young patients","volume":"78","author":"Heun-Johnson","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.bpsgos.2026.100698_bib51","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1176\/appi.ps.201600450","article-title":"Changes in coding of suicide attempts or self-harm with transition from ICD-9 to ICD-10","volume":"68","author":"Stewart","year":"2017","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.bpsgos.2026.100698_bib52","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.5335","article-title":"Overdiagnosis of attention-deficit\/hyperactivity disorder in children and adolescents: A systematic scoping review","volume":"4","author":"Kazda","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.bpsgos.2026.100698_bib53","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/pds.5547","article-title":"Core concepts in pharmacoepidemiology: Key biases arising in pharmacoepidemiologic studies","volume":"32","author":"Acton","year":"2023","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.bpsgos.2026.100698_bib54","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00213-013-2986-z","article-title":"A review of the abuse potential assessment of atomoxetine: A nonstimulant medication for attention-deficit\/hyperactivity disorder","volume":"226","author":"Upadhyaya","year":"2013","journal-title":"Psychopharmacology"},{"issue":"suppl 2S","key":"10.1016\/j.bpsgos.2026.100698_bib55","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1097\/DBP.0000000000000770","article-title":"Society for Developmental and Behavioral Pediatrics clinical practice guideline for the assessment and treatment of children and adolescents with complex attention-deficit\/hyperactivity disorder","volume":"41","author":"Barbaresi","year":"2020","journal-title":"J Dev Behav Pediatr"},{"key":"10.1016\/j.bpsgos.2026.100698_bib56","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S2215-0366(23)00332-2","article-title":"ADHD medication discontinuation and persistence across the lifespan: A retrospective observational study using population-based databases","volume":"11","author":"Brikell","year":"2023","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.bpsgos.2026.100698_bib57","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1001\/jamapsychiatry.2024.3228","article-title":"Diagnosing and treating ADHD in adults: Balancing individual benefits and population risks","volume":"81","author":"Blanco","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.bpsgos.2026.100698_bib58","doi-asserted-by":"crossref","first-page":"440","DOI":"10.3928\/00485713-20230911-06","article-title":"Development of United States guidelines for the diagnosis and treatment of adults with ADHD","volume":"53","author":"Adler","year":"2023","journal-title":"Psychiatr Ann"},{"key":"10.1016\/j.bpsgos.2026.100698_bib59","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2022.1812","article-title":"Cautions when using race and ethnicity in administrative claims data sets","volume":"3","author":"Nead","year":"2022","journal-title":"JAMA Health Forum"},{"key":"10.1016\/j.bpsgos.2026.100698_bib60","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.027426","article-title":"On the perils of conducting observational research on racial health disparities","volume":"11","author":"Pendyal","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.bpsgos.2026.100698_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2024.116309","article-title":"Association between stimulant and non-stimulant ADHD medications and completed suicide in adolescents and adults: A population-based nested case-control study","volume":"344","author":"Vasiliadis","year":"2025","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.bpsgos.2026.100698_bib62","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1600-0447.1998.tb10069.x","article-title":"Suicides hidden among undetermined deaths","volume":"98","author":"Ohberg","year":"1998","journal-title":"Acta Psychiatr Scand"}],"container-title":["Biological Psychiatry Global Open Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266717432600011X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266717432600011X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T11:16:14Z","timestamp":1778930174000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266717432600011X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S266717432600011X"],"URL":"https:\/\/doi.org\/10.1016\/j.bpsgos.2026.100698","relation":{},"ISSN":["2667-1743"],"issn-type":[{"value":"2667-1743","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacotherapies for Attention-Deficit\/Hyperactivity Disorder and Risk of Suicidal Behavior: A Within-Individual Study of Stimulants, Atomoxetine, and Alpha-2 Agonists","name":"articletitle","label":"Article Title"},{"value":"Biological Psychiatry Global Open Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpsgos.2026.100698","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 THE AUTHORS. Published by Elsevier Inc on behalf of the Society of Biological Psychiatry.","name":"copyright","label":"Copyright"}],"article-number":"100698"}}